5 FDA Decisions for Primary Care to Know from July 2026

In July, the US Food and Drug Administration (FDA) issued several regulatory decisions across preventive care, cardiometabolic risk reduction, women’s health, behavioral health, and cancer screening. The updates include first-in-category approvals, new diagnostic tools, and an expedited development designation for an investigational therapy addressing an area of high unmet need.

For primary care clinicians, the month’s decisions highlight expanding options for risk assessment and routine management. Merck’s enlicitide approval introduces the first FDA-approved oral PCSK9 inhibitor for LDL-C reduction, while Freenome and Abbott’s SimpleScreen CRC approval adds another blood-based, noninvasive screening option for average-risk adults aged 45 years and older. Roche’s cobas BV/CV assay also broadens molecular testing for symptomatic vaginitis by detecting bacterial vaginosis and Candida vaginitis from a single vaginal swab sample.

Other July updates centered on patient-centered delivery and unmet clinical need. Viatris’ Gwyn Lo approval adds a once-weekly combined hormonal contraceptive patch for appropriate candidates with BMI <30 kg/m², while Acadia’s Fast Track designation for remlifanserin reflects continued development of a potential therapy for hallucinations and delusions associated with Alzheimer disease psychosis. Together, the 5 actions underscore the FDA’s recent activity in areas frequently encountered in or referred from primary care.

1. FDA Approves First Oral PCSK9 Inhibitor to Reduce LDL-C in Adults With Hypercholesterolemia

On July 16, 2026, Merck announced FDA approval of enlicitide (Lipfendra) 20-mg tablets as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. Based on results from the phase 3 CORALreef Lipids and CORALreef HeFH trials, enlicitide reduced LDL-C by 56% and 59%, respectively, compared with placebo at week 24. The approval makes enlicitide the first FDA-approved oral PCSK9 inhibitor shown to lower LDL-C. Merck noted that an ongoing outcomes trial is evaluating whether enlicitide reduces cardiovascular morbidity and mortality.

2. FDA Approves SimpleScreen CRC Blood Test for Colorectal Cancer Screening

On July 27, 2026, Freenome and Abbott announced FDA approval of SimpleScreen CRC, a blood-based screening test for colorectal cancer in average-risk adults aged 45 years and older. Based on results from PREEMPT CRC, a prospective validation study of more than 48,000 asymptomatic adults scheduled for screening colonoscopy, SimpleScreen CRC detected colorectal cancer with 81.1% sensitivity and advanced precancerous lesions with 13.7% sensitivity. Specificity for advanced colorectal neoplasia was 90.4%. A positive result should be followed by diagnostic colonoscopy, and the test is not intended to replace diagnostic or surveillance colonoscopy in high-risk patients.

3. FDA Approves Once-Weekly Gwyn Lo Contraceptive Patch

On July 29, 2026, Viatris announced FDA approval of norelgestromin and ethinyl estradiol transdermal system (Gwyn Lo), a once-weekly combined hormonal contraceptive patch, for women of childbearing potential with a BMI <30 kg/m² who are appropriate candidates for combined hormonal contraception. Based on the phase 3 Luminous Study, Gwyn Lo demonstrated contraceptive efficacy over a year-long treatment period, with a Pearl Index of 4.14 in the efficacy evaluable population. Across 39,790 applied patches, 1.3% fully detached, and phase 1 studies supported consistent drug delivery under varying application sites and conditions. The patch delivers norelgestromin 220 mcg/day and ethinyl estradiol 20 mcg/day and is expected to reach the US market later this year.

4. FDA Clears Roche cobas BV/CV PCR Assay for Simultaneous Vaginitis Detection

On July 24, 2026, Roche announced FDA 510(k) clearance of its cobas BV/CV assay, a molecular diagnostic test for detecting bacterial vaginosis and Candida vaginitis from a single vaginal swab sample. Based on real-time polymerase chain reaction technology, the assay detects BV-associated organisms, including Gardnerella vaginalis, Atopobium vaginae, and Lactobacillus species, as well as multiple Candida species associated with Candida vaginitis. The test is intended for use in symptomatic patients and may be performed with clinician-collected or clinician-instructed self-collected vaginal swabs in a health care setting. Roche said the assay is expected to launch commercially later this year.

5. FDA Fast Tracks Remlifanserin Development for Alzheimer Disease Psychosis

On July 20, 2026, Acadia Pharmaceuticals announced FDA Fast Track designation for remlifanserin (ACP-204), an investigational serotonin 5-HT2A receptor inverse agonist, for hallucinations and delusions associated with Alzheimer disease psychosis. Based on the ongoing RADIANT clinical development program, Acadia said enrollment in the phase 2 portion is complete, with topline results expected between September and October 2026. The company has also begun screening and enrollment in phase 3 studies, but no efficacy or safety results have been reported.